No Data
No Data
No Data
No Data
No Data
What Zhejiang Orient Gene Biotech Co.,Ltd's (SHSE:688298) P/S Is Not Telling You
With a median price-to-sales (or "P/S") ratio of close to 7x in the Biotechs industry in China, you could be forgiven for feeling indifferent about Zhejiang Orient Gene Biotech Co.,Ltd's (SHSE:688298
Simply Wall StApr 30 21:00 ET
Oriental Biotech (688298.SH): Net loss of 67.3535 million yuan in the first quarter
Gelonghui, April 29丨Oriental Biotech (688298.SH) released its report for the first quarter of 2024, achieving operating income of 183 million yuan, a year-on-year decrease of 51.36%; net profit attributable to shareholders of listed companies - 67.3535 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 109 million yuan, and basic earnings per share - 0.33 yuan.
Gelonghui FinanceApr 29 06:24 ET
Zhejiang Orient Gene Biotech's Unit Gets US FDA's Nod to Register Two Products
Zhejiang Orient Gene Biotech's (SHA:688298) US unit, Hengjian Biotechnology, obtained clearance from the Food and Drug Administration to register two products, the company said in its filing on the Sh
MT NewswiresApr 23 00:22 ET
Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious
Simply Wall StMar 7 18:33 ET
Oriental Biotech (688298.SH): Stock repurchases have not been implemented
Gelonghui March 1 | Oriental Biotech (688298.SH) announced that as of the disclosure date of this announcement, the company had not implemented a stock repurchase.
Gelonghui FinanceMar 1 03:54 ET
Oriental Biotech (688298.SH): Net loss of 404 million yuan in 2023
Gelonghui, Feb. 28: Oriental Biotech (688298.SH) announced the 2023 Annual Results Report. In 2023, the company achieved total operating revenue of 824.128 million yuan, a decrease of 90.60% over the previous year; net profit attributable to the owner of the parent company after deducting non-recurring profit and loss - RMB 404.472,500, a decrease of 119.36% over the previous year.
Gelonghui FinanceFeb 28 06:02 ET
No Data
No Data